Miruvor
Sign up
The short answer

What studies of Dexamfetamine (Dexedrine) found

7papers on Dexamfetamine (Dexedrine)
11people in 2 studies testing Dexamfetamine (Dexedrine) alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: B May help

Based on the strongest evidence, the placebo trial (low certainty), for fatigue.

6 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Dexamfetamine (Dexedrine) may help for ME/CFS, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 7 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Dexamfetamine (Dexedrine) · ME/CFS is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Fatigue2 studies · 11 people took Dexamfetamine (Dexedrine) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (20 in all).

The placebo trial20 randomised · 6 weeks · 5-mg tablets, twice daily, at 8:00 a.m. and 2:00 p.m

Fatigue improved more than in the comparison group.

Dexamfetamine (Dexedrine) may reduce fatigue in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (20 in all)

Studies with no comparison group1 in the study · four years · 30 mg extended release capsules, daily (few people)

Fatigue improved.

The evidence is very uncertain about the effect of dexamfetamine (Dexedrine) on fatigue in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 2 studies
  1. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. (2003)

    People in the study
    20 randomised
    Dose
    5-mg tablets, twice daily, at 8:00 a.m. and 2:00 p.m
    Outcome
    Fatigue Severity Scale difference in mean change between groups Fatigue Severity Scale
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Sympathetic neural hyperalgesia edema syndrome as a cause of autoimmune hearing loss. (2017)

    People in the study
    1 in the study
    Dose
    30 mg extended release capsules, daily
    Outcome
    chronic fatigue syndrome improved
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Autonomic symptoms1 study · 1 (few people) person took Dexamfetamine (Dexedrine) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · four years · 30 mg extended release capsules, daily (few people)

Autonomic symptoms improved.

The evidence is very uncertain about the effect of dexamfetamine (Dexedrine) on autonomic symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Sympathetic neural hyperalgesia edema syndrome as a cause of autoimmune hearing loss. (2017)

    People in the study
    1 in the study
    Dose
    30 mg extended release capsules, daily
    Outcome
    decreased palpitations
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took Dexamfetamine (Dexedrine) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · four years · 30 mg extended release capsules, daily (few people)

Pain improved.

The evidence is very uncertain about the effect of dexamfetamine (Dexedrine) on pain in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Sympathetic neural hyperalgesia edema syndrome as a cause of autoimmune hearing loss. (2017)

    People in the study
    1 in the study
    Dose
    30 mg extended release capsules, daily
    Outcome
    decreased pelvic pain
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms1 study · 1 (few people) person took Dexamfetamine (Dexedrine) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · four years · 30 mg extended release capsules, daily (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of dexamfetamine (Dexedrine) on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Sympathetic neural hyperalgesia edema syndrome as a cause of autoimmune hearing loss. (2017)

    People in the study
    1 in the study
    Dose
    30 mg extended release capsules, daily
    Outcome
    symptoms mentioned above disappear
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily functioning1 study · 10 people took Dexamfetamine (Dexedrine) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 20 people found no clear difference; a small benefit can't be ruled out.

The placebo trial20 randomised · 6 weeks · 5-mg tablets, twice daily, at 8:00 a.m. and 2:00 p.m

No clear difference in daily functioning.

The evidence is very uncertain about the effect of dexamfetamine (Dexedrine) on daily functioning in ME/CFS. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 20 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. (2003)

    People in the study
    20 randomised
    Dose
    5-mg tablets, twice daily, at 8:00 a.m. and 2:00 p.m
    Outcome
    patient-determined outcomes
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Quality of life1 study · 10 people took Dexamfetamine (Dexedrine) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 20 people found no clear difference; a small benefit can't be ruled out.

The placebo trial20 randomised · 6 weeks · 5-mg tablets, twice daily, at 8:00 a.m. and 2:00 p.m

No clear difference in quality of life.

The evidence is very uncertain about the effect of dexamfetamine (Dexedrine) on quality of life in ME/CFS. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 20 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. (2003)

    People in the study
    20 randomised
    Dose
    5-mg tablets, twice daily, at 8:00 a.m. and 2:00 p.m
    Outcome
    Physical functioning Medical Outcomes Study 36-item Short-Form Health Survey
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    15 to 30 mg at the start

  2. 2Top dose

    Most often 15 mg (1 of 2 studies)

Doses across 2 studies

15 to 30 mg.

Each study’s dose, as printed

All papers

  1. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome.2003 · placebo trial · 20 randomised
    Summary

    The study asked whether dexamphetamine improved symptoms and quality of life in chronic fatigue syndrome. In a 6-week parallel-group, placebo-controlled trial with random allocation, 20 patients at the Newcastle Sleep Disorders Centre, Royal Newcastle Hospital, were randomly assigned: 10 to dexamphetamine and 10 to placebo. Dexamphetamine was given as 5-mg tablets twice daily, with a 2-week dose-adjustment phase followed by a 4-week stable treatment period. Outcomes were the Fatigue Severity Scale, the Medical Outcomes Study 36-item Short-Form Health Survey, patient-determined outcomes, and adverse events. Fatigue Severity Scale scores improved in 9 of 10 dexamphetamine and 4 of 10 placebo patients. Mean change was –1.45 with dexamphetamine and –0.03 with placebo; the between-group difference was statistically significant. Mean Fatigue Severity Scale score changed from 6.1 to 4.7 with dexamphetamine and from 5.9 to 5.9 with placebo; the difference in mean score was also statistically significant. Short-Form Health Survey changes were not statistically significant. There were no differences in patient-determined outcomes, and no subject recorded a change greater than 1 on the 7-point Likert scale. Five dexamphetamine patients reported reduced food consumption, three reported weight loss, and one placebo patient reported reduced food consumption; five placebo patients reported impaired balance. Withdrawals due to harms were not reported.

  2. Complete eradication of chronic long standing eczema and keratosis pilaris following treatment with dextroamphetamine sulfate.2014 · case report · 2 in the study
    Summary

    This paper reports two case reports (no comparison group, not randomised) of patients given dextroamphetamine sulfate extended release capsules. Case 1 was a 47-year-old woman with severe and frequent migraine headaches refractory to standard therapy and eczema of 30 years duration; she received 15 mg twice daily. After two months on this therapy her eczema had completely disappeared, and the total remission had lasted two years thus far. Her migraines decreased in intensity and frequency. Case 2 was a 45-year-old male with chronic fatigue syndrome and eczema of 30 years duration; he received 60 mg. His eczema almost completely disappeared and his keratosis pilaris markedly improved. The authors state that headaches and chronic fatigue syndrome in both patients markedly improved following sympathomimetic amine therapy, as did the eczema and keratosis pilaris. No untoward side effects from the medication were reported for Case 1; harms for Case 2 are not reported. The authors note that a spontaneous remission is possible but consider the treatment likely responsible for the benefit, and they hope the report will spark interest in a larger controlled trial.

  3. A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.2016 · systematic review
    Summary

    This systematic review examined drug therapies for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME). Ovid MEDLINE, EMBASE, and PubMed were searched from the beginning of their archives to March 2016. The review included 26 randomized, placebo-controlled trials that met its criteria; these trials tested 20 drug therapies. The review reports effectiveness by categories from not effective to highly effective and says no universal pharmaceutical treatment can be recommended. Hydrocortisone findings were conflicting: across studies it was reported as mildly effective, slightly effective, not effective, and moderately effective; in one study the well-being improvement was not significant, and Blockmans et al found no clinical improvement. Rituximab was reported to produce a significant and lasting improvement, but the review states it is premature to conclude a lasting improvement in primary assessed domains; primary end points were evaluated for 3 months and secondary end points up to 12 months. For intravenous immunoglobulin, Rowe reported headache, fatigue, and difficulty concentrating significantly worse in the intervention group after the first infusion, with no differences after the third and final infusion. The review states no pharmaceutical therapy resulted in severe adverse events. It notes nefazodone was discontinued in 2004 after patients developed hepatic and visual disorders. Forsyth et al and Young each had N = 26; Young lacked male participants in the intervention cohort. The authors state that no clear recommended pharmaceutical therapy for CFS/ME exists and call for standardized diagnostic criteria and outcome measurements.

  4. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
    Summary

    This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.

  5. Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
    Summary

    This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.

  6. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
    Summary

    This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime